Csti-300 (smp-100); a novel 5-ht3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndrome

HIGHLIGHTS

• who: / and collaborators from the Neuropharmacology Research Group, Institute of Clinical Sciences (AR., G.G., A.J.C., C.A.B., O.Q., N.M.B.) and Institute of Immunology and Immunotherapy (Z.S.), College of Medical and Dental Sciences and DB, Diagnostics, Drugs, Devices and Biomarkers, Cancer Research UK Clinical Trials Unit (K.B.), University of Birmingham, Edgbaston, Birmingham, United Kingdom have published the Article: CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome, in the Journal: (JOURNAL)
• what: This . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.